- Home
- OM vs DYAI Comparison
OM vs DYAI Comparison
Compare OM & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- DYAI
- Stock Information
- Founded
- OM 2003
- DYAI 1979
- Country
- OM United States
- DYAI United States
- Employees
- OM N/A
- DYAI N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OM Health Care
- DYAI Health Care
- Exchange
- OM Nasdaq
- DYAI Nasdaq
- Market Cap
- OM 50.5M
- DYAI 54.4M
- IPO Year
- OM 2020
- DYAI 2004
- Fundamental
- Price
- OM $11.01
- DYAI $1.23
- Analyst Decision
- OM Buy
- DYAI Strong Buy
- Analyst Count
- OM 2
- DYAI 1
- Target Price
- OM $45.00
- DYAI $6.00
- AVG Volume (30 Days)
- OM 141.8K
- DYAI 31.1K
- Earning Date
- OM 05-07-2025
- DYAI 05-13-2025
- Dividend Yield
- OM N/A
- DYAI N/A
- EPS Growth
- OM N/A
- DYAI N/A
- EPS
- OM N/A
- DYAI N/A
- Revenue
- OM $113,689,000.00
- DYAI $3,495,389.00
- Revenue This Year
- OM $8.98
- DYAI $117.40
- Revenue Next Year
- OM $12.74
- DYAI N/A
- P/E Ratio
- OM N/A
- DYAI N/A
- Revenue Growth
- OM N/A
- DYAI 20.58
- 52 Week Low
- OM $5.85
- DYAI $0.93
- 52 Week High
- OM $78.30
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- OM 52.11
- DYAI 40.54
- Support Level
- OM $10.30
- DYAI $1.20
- Resistance Level
- OM $11.65
- DYAI $1.28
- Average True Range (ATR)
- OM 1.20
- DYAI 0.07
- MACD
- OM 0.08
- DYAI -0.00
- Stochastic Oscillator
- OM 65.42
- DYAI 25.93
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.